Your session is about to expire
← Back to Search
Obinutuzumab for Lupus Nephritis (POSTERITY Trial)
POSTERITY Trial Summary
This trial will study whether the drug obinutuzumab is safe and effective in treating adolescent patients with lupus nephritis.
POSTERITY Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPOSTERITY Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 229 Patients • NCT02264574POSTERITY Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have severe brain-related lupus symptoms like vision loss, uncontrolled seizures, confusion, or difficulty moving.I have not had a serious infection or been treated with IV or oral anti-infectives recently.You have a history of weak immune system or severe blood disorders.My kidney biopsy shows I have Class III or IV lupus nephritis.I have a history of serious, recurring infections.You have a specific type of lupus nephritis called Class V LN.I am between 12 and 17 years old.More than half of the kidney's glomeruli show signs of scarring on a biopsy.I cannot tolerate or am not allowed to have the study's treatments.I have not had any cancer except for treated skin cancer in the last 5 years.My kidney biopsy shows I only have chronic damage, with no active disease.I have a quickly worsening kidney condition.You are currently misusing alcohol or drugs, or have a history of misusing them.I do not have any severe illnesses that would stop me from joining the study.I am between 5 and 11 years old.I have Class III or IV kidney disease, and may also have Class V.I have been diagnosed with SLE as per the SLICC 2012 criteria.You have too much protein in your urine, based on a test done in the morning.I've had a strong steroid treatment for my lupus nephritis in the last year.
- Group 1: Open-Label Obinutuzumab
- Group 2: Blinded Obinutuzumab
- Group 3: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there still an opportunity for people to join this experimental endeavor?
"Confirmed. The clinical trial outlined on the clinicaltrials.gov is actively recruiting participants, having been posted in May of 2022 and recently updated in November of that same year. Recruitment requires 30 volunteers from 11 separate medical centres."
What is the current number of participants in this research endeavor?
"Genentech, Inc., the sponsor of this trial, is calling for a minimum of 30 participants that meet enrollment requirements to execute their study. These individuals will be recruited from Nationwide Children's Hospital in Columbus and University of California San Francisco in San Francisco."
What maladies has Obinutuzumab been utilized to combat?
"Obinutuzumab is frequently utilized to mitigate discomfort, but has also been found to posses efficacy in the treatment of conditions such as ulcerative colitis, varicella-zoster virus acute retinal necrosis, and subarachnoid block."
Is this research endeavor open to individuals more than two decades of age?
"Those wishing to participate in this clinical trial must be between 12 and 17 years old. There are 168 trials geared towards minors while the elderly have access to 598 different studies."
What is the number of medical centers participating in this research endeavor?
"This medical study is taking place at 11 different locations, such as Nationwide Children's Hospital in Columbus, University of California San Francisco in San Francisco and Children's Hospital Colorado, Anchutz Medical Campus in Aurora."
Is it feasible for me to become a participant in this experimentation?
"This clinical trial is recruiting 30 juvenile patients with lupus nephritis, aged between 12 and 17. Notably these individuals must have either Class III or IV Lupus Nephritis, however those exhibiting solely Class V symptoms are not eligible for participation."
Has Obinutuzumab been granted regulatory approval by the Food and Drug Administration?
"The safety of Obinutuzumab is ranked at a 2, as it has yet to be proven efficacious but there are some studies that suggest its security."
What other evidence exists regarding the efficacy of Obinutuzumab?
"Currently, 698 active studies are exploring the efficacy of Obinutuzumab with 165 trials in phase 3. Although Philadelphia is home to multiple research sites running these clinical trials, there are over 20 thousand locations offering this medication globally."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger